Company profile

Edward A. Pesicka
Fiscal year end
Former names
IRS number

OMI stock data



5 Aug 20
19 Sep 20
31 Dec 20


Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
1 Sep 20 Robert J Henkel Phantom Stock Common Stock Grant Aquire A No 16.4 476 7.81K 36,410
1 Sep 20 Mark F Mcgettrick Phantom Stock Common Stock Grant Aquire A No 16.4 2,210 36.24K 105,310
10 Aug 20 Riordan Michael C Common Stock Buy Aquire P No 13.6725 20,000 273.45K 20,000
7 Aug 20 Beck Mark A Phantom Stock Common Stock Grant Aquire A No 0 18 0 40,295
7 Aug 20 Sledd Robert C Common Stock Buy Aquire P No 13.1 10,000 131K 10,000
7 Aug 20 Sledd Robert C Common Stock Buy Aquire P No 12.89 10,000 128.9K 10,000
88.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 188 185 +1.6%
Opened positions 43 36 +19.4%
Closed positions 40 32 +25.0%
Increased positions 59 61 -3.3%
Reduced positions 53 52 +1.9%
13F shares
Current Prev Q Change
Total value 1.45B 2.52B -42.4%
Total shares 56.1M 55.1M +1.8%
Total puts 119K 92.3K +28.9%
Total calls 416.1K 629.3K -33.9%
Total put/call ratio 0.3 0.1 +95.0%
Largest owners
Shares Value Change
BLK BlackRock 9.79M $74.57M +1.3%
Vanguard 5.09M $38.82M -1.7%
Dimensional Fund Advisors 4.6M $35.05M -7.2%
JPM JPMorgan Chase & Co. 2.99M $22.75M +9.8%
STT State Street 2.67M $20.35M +0.8%
Renaissance Technologies 2.41M $18.34M -20.6%
Royce & Associates 1.92M $14.64M -6.3%
LSV Asset Management 1.79M $13.64M -1.2%
Deerfield Management 1.48M $11.26M NEW
Smith, Graham & Co., Investment Advisors 1.13M $8.58M +5.3%
Largest transactions
Shares Bought/sold Change
Deerfield Management 1.48M +1.48M NEW
GS Goldman Sachs 486.04K -1.2M -71.2%
Point72 Asset Management 773.05K +700.55K +966.3%
MS Morgan Stanley 307.63K -683.79K -69.0%
Renaissance Technologies 2.41M -624.45K -20.6%
Schroder Investment Management 579.34K +579.34K NEW
Grantham, Mayo, Van Otterloo & Co. 492.3K +492.3K NEW
Dimensional Fund Advisors 4.6M -354.3K -7.2%
Panagora Asset Management 625 -353.22K -99.8%
Acadian Asset Management 864.41K +344.73K +66.3%

Financial report summary

  • We face competition and accelerating pricing pressure.
  • We have significant concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations.
  • Our operating income is dependent on certain significant domestic suppliers.
  • Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a customer that has a substantial amount owed to us.
  • Changing conditions in the United States healthcare industry may impact our results of operations.
  • We may not be able to generate sufficient cash to service our debt and other obligations.
  • Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
  • An interruption in the ability of our business to manufacture products may have a material adverse effect on our business.
  • An inability to obtain key components, raw materials or manufactured products from third parties may have a material adverse effect on our Global Products segment.
  • We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business.
  • We must obtain clearance or approval from the appropriate regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial costs, delays and limitations on the types and uses of products we can bring to market, any of which could have a material adverse effect on our business.
  • Our inability to adequately integrate acquisitions could have a material adverse effect on our operations.
  • Our Global Products segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations.
  • Our business and operations depend on the proper functioning of critical facilities, supply chain and distribution networks.
  • Our investment in Fusion5 may continue to incur losses.
  • We are subject to stringent regulatory and licensing requirements.
  • Compliance with the terms and conditions of Byram’s Corporate Integrity Agreement requires significant resources and, if we fail to comply, we could be subject to penalties or excluded from participation in government healthcare programs, which could seriously harm our results of operations, liquidity and financial condition.
  • General economic conditions may adversely affect demand for our products and services.
  • We operate within the European Union and therefore may be affected by the United Kingdom's withdrawal from the European Union.
  • Our continued success is substantially dependent on positive perceptions of our reputation.
  • We may experience competition from third-party online commerce sites.
  • Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
  • Recent significant changes to our executive leadership team and any future loss of members of such team, and the resulting management transitions might harm our future operating results.
  • Our goodwill may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • The market price for our common stock may be highly volatile.
  • We cannot assure you that the proposed Movianto sale will be completed.
  • We and the Movianto business will be subject to business uncertainties while the sale is pending that could adversely affect our business and the Movianto business.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company. On June 18, 2020 (the Divestiture Date), we completed the previously announced divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $133 million. The Divestiture provides us with a greater ability to focus on and invest in our differentiated products, services and U.S. distribution businesses. A portion of the net proceeds was used to repurchase $54.1 million of our 2021 Notes through a tender offer (see Note 6, “Debt”). We recorded losses of $56.4 million and $65.5 million, respectively, in connection with the Divestiture for the three and six months ended June 30, 2020.
  • We have entered into transition services agreements with a subsidiary of the Buyer, pursuant to which we and a subsidiary of the Buyer will provide to each other various transitional services. Transition service expenses and reimbursements were immaterial for the three and six months ended June 30, 2020.
Content analysis ?
H.S. sophomore Good
New words: adequacy, adjudication, audit, buyer, conducting, disposal, drew, Dublin, expended, guarantor, Home, independent, judicial, likelihood, matter, merit, methodology, output, point, pursue, regularly, reimbursed, repaid, resolve, SAS, sourcing, surrender, taxable, uncertain, Walden
Removed: alternative, case, classification, controlled, disclosed, ensure, exist, health, intended, land, large, largely, minimum, Prime, set, transportation, voting